DOCSLIB.ORG

Supplementary Material a Gene Expression Signature Associated

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Supplementary Material A Gene Expression Signature Associated With Overall Survival in Patients With Hepatocellular Carcinoma Suggests a New Treatment Strategy Jean-Pierre Gillet, Jesper B. Andersen, James P. Madigan, Sudhir Varma, Rachel K. Bagni, Katie Powell, William E. Burgan, Chung-Pu Wu, Anna Maria Calcagno, Suresh V. Ambudkar, Snorri S. Thorgeirsson, Michael M. Gottesman Journal: Molecular Pharmacology Table S1: Compounds highlighted through the Connectivity Map tool Rank for Name of drug on Connectivity Map score - Number of Connectivity Map Probability of getting Proportion of other drugs Drug signature is drug, rated Connectivity Map similarity between the experiments used score normalized an enrichment this that share this same significant for what according to gene expression signature to compute mean using scores from high if there is no signature (smaller values percent of the "n" p-value of drug and the signature similarity random selections of connection between mean that the signature is experiments? used as input genes drug signature and very specific to this input signature particular drug) Rank C-map name Mean n Enrichment p Specificity Percent non-null 1 8-azaguanine 0.916 4 0.975 0 0 100 2 adiphenine -0.765 5 -0.909 0 0.0242 100 3 trichostatin A 0.485 182 0.306 0 0.7204 73 4 tanespimycin 0.474 62 0.297 0 0.3834 72 5 apigenin 0.851 4 0.937 0.00002 0.0234 100 6 0175029-0000 0.797 6 0.86 0.00002 0.0177 100 7 thiamphenicol -0.711 5 -0.903 0.00004 0 100 8 thioguanosine 0.821 4 0.902 0.0001 0.0177 100 9 viomycin -0.723 4 -0.9 0.00016 0.0144 100 10 GW-8510 0.846 4 0.886 0.00016 0.0939 100 11 heptaminol -0.676 5 -0.802 0.00068 0.0137 100 12 biperiden -0.644 5 -0.783 0.00086 0.0408 100 13 Prestwick-692 -0.719 4 -0.852 0.00092 0.0068 100 14 trifluoperazine 0.542 16 0.466 0.00094 0.274 75 15 gentamicin -0.621 4 -0.846 0.00101 0.0263 100 16 thiostrepton 0.753 4 0.835 0.00115 0.0539 100 17 phenoxybenzamine 0.8 4 0.829 0.00127 0.2525 100 18 fludrocortisone -0.319 8 -0.634 0.00136 0.0704 62 19 skimmianine 0.76 4 0.826 0.00143 0.0082 100 20 felbinac -0.695 4 -0.831 0.00147 0.0355 100 21 lisuride -0.528 5 -0.756 0.0016 0.0492 100 22 trimethobenzamide -0.536 5 -0.751 0.00176 0.0201 100 23 vorinostat 0.539 12 0.513 0.00198 0.4422 75 24 nadolol -0.57 4 -0.812 0.00233 0.0615 100 25 Gly-His-Lys -0.677 3 -0.892 0.0024 0.0149 100 26 daunorubicin 0.733 4 0.792 0.00366 0.0758 100 27 isoflupredone -0.713 3 -0.876 0.00385 0.1083 100 28 medrysone 0.763 6 0.667 0.00385 0.0787 100 29 3-acetamidocoumarin -0.679 4 -0.787 0.00412 0.0844 100 30 isoxicam -0.55 5 -0.711 0.00429 0.0811 80 31 luteolin 0.785 4 0.78 0.00442 0.073 100 32 Prestwick-983 -0.611 3 -0.869 0.00445 0.0206 100 33 tyloxapol 0.755 4 0.779 0.0045 0.0182 100 34 camptothecin 0.742 3 0.865 0.00463 0.2098 100 35 phthalylsulfathiazole 0.771 5 0.711 0.00473 0.0354 100 36 vincamine -0.373 6 -0.653 0.00475 0.0529 66 37 trazodone 0.749 3 0.863 0.00481 0.0373 100 38 meticrane 0.789 5 0.709 0.00495 0.028 100 39 chloropyrazine -0.582 4 -0.779 0.00497 0.0195 100 40 Prestwick-1082 -0.652 3 -0.862 0.00535 0.082 100 41 gabexate -0.589 4 -0.77 0.00567 0.052 100 42 podophyllotoxin -0.658 4 -0.768 0.00577 0.0686 100 43 chenodeoxycholic acid -0.552 4 -0.766 0.00603 0.0615 100 44 PHA-00745360 -0.394 8 -0.561 0.00654 0.1395 75 45 colistin -0.553 4 -0.762 0.00658 0.0231 100 46 atractyloside -0.53 5 -0.686 0.00703 0.0303 80 47 finasteride -0.35 6 -0.634 0.00709 0.1402 66 48 chrysin 0.775 3 0.844 0.00745 0.0351 100 49 chlorhexidine -0.306 5 -0.682 0.00747 0.015 60 50 Prestwick-1103 -0.627 4 -0.752 0.00762 0.0397 100 51 quinpirole -0.554 4 -0.752 0.00762 0.0148 100 52 norcyclobenzaprine 0.73 4 0.749 0.00762 0.0546 100 53 Prestwick-691 -0.683 3 -0.842 0.00783 0.0592 100 54 canadine -0.575 4 -0.747 0.00812 0.0604 100 55 thioperamide -0.457 5 -0.677 0.00815 0.0672 80 56 isometheptene -0.485 4 -0.747 0.00818 0.0414 100 57 monensin -0.289 6 -0.627 0.00842 0.1545 50 58 0297417-0002B 0.747 3 0.838 0.00843 0.0947 100 59 Prestwick-1084 0.734 4 0.74 0.00875 0.0103 100 60 merbromin -0.479 5 -0.671 0.00889 0.0732 80 61 etiocholanolone -0.52 6 -0.623 0.00918 0.1688 83 62 penbutolol -0.664 3 -0.833 0.00933 0.0074 100 63 timolol -0.432 4 -0.737 0.00953 0.0448 75 64 CP-320650-01 -0.331 8 -0.541 0.01019 0.1223 75 65 levomepromazine -0.428 4 -0.732 0.01038 0.0094 75 66 bufexamac 0.694 4 0.731 0.0104 0.0211 100 67 sulfadimethoxine -0.536 5 -0.662 0.01043 0.1407 80 68 furazolidone -0.403 4 -0.732 0.01044 0.0191 75 69 procaine 0.654 5 0.667 0.01077 0.0522 100 70 aciclovir -0.523 6 -0.612 0.01104 0.0729 83 71 diphenhydramine -0.603 5 -0.658 0.01137 0.0963 80 72 mebhydrolin -0.537 4 -0.726 0.01158 0.0168 75 73 pindolol -0.441 5 -0.657 0.01158 0.0206 80 74 pargyline 0.666 4 0.72 0.01237 0.0472 100 75 pheneticillin -0.457 4 -0.721 0.01239 0.0327 75 76 alprostadil -0.429 7 -0.563 0.01247 0.04 71 77 Prestwick-642 -0.462 4 -0.718 0.01271 0.0552 75 78 ajmaline -0.649 3 -0.814 0.01278 0.0355 100 79 cycloserine 0.678 4 0.718 0.01297 0.0385 100 80 repaglinide 0.674 4 0.717 0.01307 0.0741 100 81 dicycloverine -0.32 5 -0.645 0.01402 0.0382 60 82 LY-294002 0.375 61 0.198 0.0146 0.651 65 83 chlorpromazine 0.495 19 0.351 0.01462 0.0705 84 84 H-7 0.651 4 0.704 0.01597 0.25 100 85 prochlorperazine 0.511 16 0.374 0.01604 0.4029 81 86 carteolol -0.342 4 -0.703 0.01605 0.0296 50 87 dapsone -0.41 5 -0.635 0.01668 0.084 80 88 resveratrol 0.619 9 0.487 0.01689 0.3382 100 89 diethylstilbestrol -0.307 6 -0.588 0.01706 0.082 83 90 nitrofurantoin 0.666 5 0.641 0.01718 0.0467 100 91 tranexamic acid -0.484 5 -0.632 0.01738 0.2282 80 92 guanabenz -0.528 5 -0.632 0.01748 0.1308 80 93 methyldopate -0.347 4 -0.698 0.01751 0.0438 75 94 midodrine -0.389 5 -0.631 0.01762 0.1579 60 95 ifenprodil 0.689 4 0.696 0.01774 0.0435 100 96 tetracycline -0.401 5 -0.627 0.01874 0.0566 60 97 omeprazole 0.73 4 0.692 0.01884 0.1009 100 98 vinblastine -0.616 3 -0.79 0.01893 0.1145 100 99 bisacodyl 0.67 4 0.691 0.01898 0.0851 100 100 isoniazid -0.414 5 -0.624 0.01949 0.0994 80 101 lasalocid -0.437 4 -0.691 0.01959 0.1296 75 102 iohexol -0.495 4 -0.688 0.02037 0.0511 75 103 cetirizine 0.717 4 0.685 0.02093 0.0571 100 104 levobunolol -0.443 4 -0.685 0.02137 0.1154 75 105 naringenin -0.392 4 -0.684 0.02172 0.0968 50 106 sulfamonomethoxine -0.42 4 -0.679 0.02357 0.0861 50 107 hexetidine -0.453 4 -0.677 0.02401 0.0769 75 108 imipenem 0.667 4 0.676 0.02409 0.0153 100 109 pyrithyldione -0.6 4 -0.677 0.02425 0.0775 75 110 bepridil 0.689 4 0.675 0.02441 0.1722 100 111 iproniazid -0.299 5 -0.611 0.02473 0.0602 60 112 calcium folinate -0.527 5 -0.611 0.02489 0.1221 80 113 streptozocin -0.389 4 -0.674 0.02524 0.0556 75 114 ethotoin 0.661 6 0.564 0.02525 0.0661 100 115 PF-00539745-00 -0.517 3 -0.769 0.02538 0.0889 100 116 iopamidol -0.48 4 -0.673 0.02572 0.0588 75 117 antimycin A 0.69 5 0.613 0.02577 0.1011 100 118 ellipticine 0.64 4 0.669 0.02674 0.2265 75 119 propafenone 0.698 4 0.668 0.02688 0.06 100 120 iocetamic acid -0.344 4 -0.668 0.02741 0 75 121 alpha-estradiol 0.466 16 0.353 0.02747 0.2558 81 122 DL-thiorphan 0.799 2 0.883 0.02789 0.1029 100 123 dipyridamole 0.663 6 0.558 0.02827 0.0872 100 124 methazolamide 0.671 4 0.664 0.02865 0.0283 100 125 harmine 0.632 4 0.661 0.03032 0.084 75 126 trihexyphenidyl -0.427 3 -0.754 0.03047 0.0902 100 127 sulfametoxydiazine 0.714 4 0.66 0.03077 0.0849 100 128 clemizole 0.682 5 0.6 0.03104 0.0788 100 129 naproxen -0.218 9 -0.456 0.03155 0.0915 55 130 clorsulon -0.533 4 -0.657 0.03173 0.078 75 131 Prestwick-665 0.675 5 0.599 0.03192 0.0488 100 132 meteneprost -0.4 4 -0.654 0.03338 0.1797 75 133 halcinonide 0.607 5 0.595 0.03362 0.0584 100 134 triflupromazine -0.372 4 -0.653 0.03364 0.0172 75 135 dequalinium chloride 0.697 4 0.653 0.03374 0.0797 100 136 chlortalidone -0.398 4 -0.651 0.03481 0.0651 75 137 sulconazole 0.716 4 0.65 0.03553 0.1438 100 138 ceforanide -0.41 4 -0.649 0.03567 0.0659 75 139 6-azathymine 0.716 4 0.647 0.03724 0.0507 100 140 nifenazone -0.318 5 -0.581 0.03831 0.0395 80 141 glafenine 0.63 4 0.645 0.03841 0.0709 100 142 ketotifen -0.407 4 -0.643 0.03863 0.1148 75 143 trioxysalen 0.736 4 0.642 0.04018 0.1044 100 144 oxybenzone -0.366 4 -0.64 0.04024 0.1127 75 145 alsterpaullone 0.778 3 0.726 0.04046 0.2791 100 146 scriptaid 0.691 3 0.725 0.04054 0.2685 100 147 homatropine -0.246 5 -0.577 0.04095 0.0633 60 148 protriptyline 0.604 4 0.639 0.04132 0.0894 75 149 copper sulfate -0.21 4 -0.637 0.04176 0.0294 75 150 acepromazine 0.69 4 0.637 0.04245 0.0444 100 151 ampyrone -0.352 5 -0.572 0.0433 0.0694 80 152 withaferin A 0.646 4 0.635 0.04337 0.3211 100 153 ebselen 0.73 3 0.72 0.04351 0.196 100 154 morantel 0.727 5 0.575 0.04376 0.0686 100 155 benzocaine -0.374 4 -0.634 0.04386 0.1611 75 156 eucatropine 0.592 6 0.526 0.04483 0.1583 100 157 cloperastine 0.657 6 0.526 0.04531 0.2643 100 158 guanadrel -0.398 5 -0.567 0.046 0.1812 60 159 acetylsalicylic acid 0.439 13 0.365 0.04631 0.096 76 160 beta-escin 0.602 6 0.524 0.04674 0.1989 100 161 hexestrol 0.685 4 0.629 0.04697 0.1714 100 162 dextromethorphan 0.571 4 0.628 0.04812 0.0522 75 163 acemetacin -0.383 4 -0.626 0.04824 0.1716 75.
Recommended publications
  • SYNTHESIS and STRUCTURE ACTIVITY STUDIES of NOVEL H3-RECEPTOR HISTAMINE ANTAGONISTS. a Thesis Presented in Partial Fulfilment Of

    SYNTHESIS and STRUCTURE ACTIVITY STUDIES of NOVEL H3-RECEPTOR HISTAMINE ANTAGONISTS. a Thesis Presented in Partial Fulfilment Of

    1 SYNTHESIS AND STRUCTURE ACTIVITY STUDIES OF NOVEL H3-RECEPTOR HISTAMINE ANTAGONISTS. A thesis presented in partial fulfilment of the requirements for the Doctor of Philosophy Degree of the University of London SEYED KIUMARS HOSSEINI Department of Chemistry University College London September 1991 Attention is drawn to the fact that copyright of this thesis rests with its author. This copy of the thesis has been supplied on condition that anyone who consults it is understood to recognise that the copyright rests with its author and that no quotation from the thesis and no information derived from it may be published without prior consent of the author. Signature: Date..^*^^~ ProQuest Number: 10609847 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a com plete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest 10609847 Published by ProQuest LLC(2017). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States C ode Microform Edition © ProQuest LLC. ProQuest LLC. 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106- 1346 2 Acknowledgements I would like to express my gratitude for the guidance and generous support of Prof. C. R. Ganellin and for the financial support of Bioproject in association with Centre Paul Broca de rinserm, Paris. Thanks to Prof.
  • WO 2015/179249 Al 26 November 2015 (26.11.2015) P O P C T

    WO 2015/179249 Al 26 November 2015 (26.11.2015) P O P C T

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/179249 Al 26 November 2015 (26.11.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12N 15/11 (2006.01) A61K 38/08 (2006.01) kind of national protection available): AE, AG, AL, AM, C12N 15/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) Number: International Application DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2015/031213 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, 15 May 2015 (15.05.2015) MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (25) Filing Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (26) Publication Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 62/000,43 1 19 May 2014 (19.05.2014) US kind of regional protection available): ARIPO (BW, GH, 62/129,746 6 March 2015 (06.03.2015) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (72) Inventors; and TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicants : GELLER, Bruce, L.
  • Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications

    Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications

    International Journal of Molecular Sciences Review Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications Daniel Fernández-Villa 1, Maria Rosa Aguilar 1,2 and Luis Rojo 1,2,* 1 Instituto de Ciencia y Tecnología de Polímeros, Consejo Superior de Investigaciones Científicas, CSIC, 28006 Madrid, Spain; [email protected] (D.F.-V.); [email protected] (M.R.A.) 2 Consorcio Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina, 28029 Madrid, Spain * Correspondence: [email protected]; Tel.: +34-915-622-900 Received: 18 September 2019; Accepted: 7 October 2019; Published: 9 October 2019 Abstract: Bacterial, protozoan and other microbial infections share an accelerated metabolic rate. In order to ensure a proper functioning of cell replication and proteins and nucleic acids synthesis processes, folate metabolism rate is also increased in these cases. For this reason, folic acid antagonists have been used since their discovery to treat different kinds of microbial infections, taking advantage of this metabolic difference when compared with human cells. However, resistances to these compounds have emerged since then and only combined therapies are currently used in clinic. In addition, some of these compounds have been found to have an immunomodulatory behavior that allows clinicians using them as anti-inflammatory or immunosuppressive drugs. Therefore, the aim of this review is to provide an updated state-of-the-art on the use of antifolates as antibacterial and immunomodulating agents in the clinical setting, as well as to present their action mechanisms and currently investigated biomedical applications. Keywords: folic acid antagonists; antifolates; antibiotics; antibacterials; immunomodulation; sulfonamides; antimalarial 1.
  • Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation

    Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation

    www.sciencemag.org/cgi/content/full/327/5963/348/DC1 Supporting Online Material for Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation Jason Rihel,* David A. Prober, Anthony Arvanites, Kelvin Lam, Steven Zimmerman, Sumin Jang, Stephen J. Haggarty, David Kokel, Lee L. Rubin, Randall T. Peterson, Alexander F. Schier* *To whom correspondence should be addressed. E-mail: [email protected] (A.F.S.); [email protected] (J.R.) Published 15 January 2010, Science 327, 348 (2010) DOI: 10.1126/science.1183090 This PDF file includes: Materials and Methods SOM Text Figs. S1 to S18 Table S1 References Supporting Online Material Table of Contents Materials and Methods, pages 2-4 Supplemental Text 1-7, pages 5-10 Text 1. Psychotropic Drug Discovery, page 5 Text 2. Dose, pages 5-6 Text 3. Therapeutic Classes of Drugs Induce Correlated Behaviors, page 6 Text 4. Polypharmacology, pages 6-7 Text 5. Pharmacological Conservation, pages 7-9 Text 6. Non-overlapping Regulation of Rest/Wake States, page 9 Text 7. High Throughput Behavioral Screening in Practice, page 10 Supplemental Figure Legends, pages 11-14 Figure S1. Expanded hierarchical clustering analysis, pages 15-18 Figure S2. Hierarchical and k-means clustering yield similar cluster architectures, page 19 Figure S3. Expanded k-means clustergram, pages 20-23 Figure S4. Behavioral fingerprints are stable across a range of doses, page 24 Figure S5. Compounds that share biological targets have highly correlated behavioral fingerprints, page 25 Figure S6. Examples of compounds that share biological targets and/or structural similarity that give similar behavioral profiles, page 26 Figure S7.
  • Histamine Receptors

    Histamine Receptors

    Tocris Scientific Review Series Tocri-lu-2945 Histamine Receptors Iwan de Esch and Rob Leurs Introduction Leiden/Amsterdam Center for Drug Research (LACDR), Division Histamine is one of the aminergic neurotransmitters and plays of Medicinal Chemistry, Faculty of Sciences, Vrije Universiteit an important role in the regulation of several (patho)physiological Amsterdam, De Boelelaan 1083, 1081 HV, Amsterdam, The processes. In the mammalian brain histamine is synthesised in Netherlands restricted populations of neurons that are located in the tuberomammillary nucleus of the posterior hypothalamus.1 Dr. Iwan de Esch is an assistant professor and Prof. Rob Leurs is These neurons project diffusely to most cerebral areas and have full professor and head of the Division of Medicinal Chemistry of been implicated in several brain functions (e.g. sleep/ the Leiden/Amsterdam Center of Drug Research (LACDR), VU wakefulness, hormonal secretion, cardiovascular control, University Amsterdam, The Netherlands. Since the seventies, thermoregulation, food intake, and memory formation).2 In histamine receptor research has been one of the traditional peripheral tissues, histamine is stored in mast cells, eosinophils, themes of the division. Molecular understanding of ligand- basophils, enterochromaffin cells and probably also in some receptor interaction is obtained by combining pharmacology specific neurons. Mast cell histamine plays an important role in (signal transduction, proliferation), molecular biology, receptor the pathogenesis of various allergic conditions. After mast cell modelling and the synthesis and identification of new ligands. degranulation, release of histamine leads to various well-known symptoms of allergic conditions in the skin and the airway system. In 1937, Bovet and Staub discovered compounds that antagonise the effect of histamine on these allergic reactions.3 Ever since, there has been intense research devoted towards finding novel ligands with (anti-) histaminergic activity.
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

    PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
  • Drug Delivery Systems on Leprosy Therapy: Moving Towards Eradication?

    Drug Delivery Systems on Leprosy Therapy: Moving Towards Eradication?

    pharmaceutics Review Drug Delivery Systems on Leprosy Therapy: Moving Towards Eradication? Luíse L. Chaves 1,2,*, Yuri Patriota 2, José L. Soares-Sobrinho 2 , Alexandre C. C. Vieira 1,3, Sofia A. Costa Lima 1,4 and Salette Reis 1,* 1 Laboratório Associado para a Química Verde, Rede de Química e Tecnologia, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, 4050-313 Porto, Portugal; [email protected] (A.C.C.V.); slima@ff.up.pt (S.A.C.L.) 2 Núcleo de Controle de Qualidade de Medicamentos e Correlatos, Universidade Federal de Pernambuco, Recife 50740-521, Brazil; [email protected] (Y.P.); [email protected] (J.L.S.-S.) 3 Laboratório de Tecnologia dos Medicamentos, Universidade Federal de Pernambuco, Recife 50740-521, Brazil 4 Cooperativa de Ensino Superior Politécnico e Universitário, Instituto Universitário de Ciências da Saúde, 4585-116 Gandra, Portugal * Correspondence: [email protected] (L.L.C.); shreis@ff.up.pt (S.R.) Received: 30 October 2020; Accepted: 4 December 2020; Published: 11 December 2020 Abstract: Leprosy disease remains an important public health issue as it is still endemic in several countries. Mycobacterium leprae, the causative agent of leprosy, presents tropism for cells of the reticuloendothelial and peripheral nervous system. Current multidrug therapy consists of clofazimine, dapsone and rifampicin. Despite significant improvements in leprosy treatment, in most programs, successful completion of the therapy is still sub-optimal. Drug resistance has emerged in some countries. This review discusses the status of leprosy disease worldwide, providing information regarding infectious agents, clinical manifestations, diagnosis, actual treatment and future perspectives and strategies on targets for an efficient targeted delivery therapy.
  • In Vitro Pharmacology of Clinically Used Central Nervous System-Active Drugs As Inverse H1 Receptor Agonists

    In Vitro Pharmacology of Clinically Used Central Nervous System-Active Drugs As Inverse H1 Receptor Agonists

    0022-3565/07/3221-172–179$20.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 322, No. 1 Copyright © 2007 by The American Society for Pharmacology and Experimental Therapeutics 118869/3215703 JPET 322:172–179, 2007 Printed in U.S.A. In Vitro Pharmacology of Clinically Used Central Nervous System-Active Drugs as Inverse H1 Receptor Agonists R. A. Bakker,1 M. W. Nicholas,2 T. T. Smith, E. S. Burstein, U. Hacksell, H. Timmerman, R. Leurs, M. R. Brann, and D. M. Weiner Department of Medicinal Chemistry, Leiden/Amsterdam Center for Drug Research, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands (R.A.B., H.T., R.L.); ACADIA Pharmaceuticals Inc., San Diego, California (R.A.B., M.W.N., T.T.S., E.S.B., U.H., M.R.B., D.M.W.); and Departments of Pharmacology (M.R.B.), Neurosciences (D.M.W.), and Psychiatry (D.M.W.), University of California, San Diego, California Received January 2, 2007; accepted March 30, 2007 Downloaded from ABSTRACT The human histamine H1 receptor (H1R) is a prototypical G on this screen, we have reported on the identification of 8R- protein-coupled receptor and an important, well characterized lisuride as a potent stereospecific partial H1R agonist (Mol target for the development of antagonists to treat allergic con- Pharmacol 65:538–549, 2004). In contrast, herein we report on jpet.aspetjournals.org ditions. Many neuropsychiatric drugs are also known to po- a large number of varied clinical and chemical classes of drugs tently antagonize this receptor, underlying aspects of their side that are active in the central nervous system that display potent effect profiles.
  • Food Sample Preparation for the Determination of Sulfonamides by High-Performance Liquid Chromatography: State-Of-The-Art

    Food Sample Preparation for the Determination of Sulfonamides by High-Performance Liquid Chromatography: State-Of-The-Art

    separations Review Food Sample Preparation for the Determination of Sulfonamides by High-Performance Liquid Chromatography: State-of-the-Art Dimitrios Bitas 1, Abuzar Kabir 2 ID , Marcello Locatelli 3 ID and Victoria Samanidou 1,* ID 1 Laboratory of Analytical Chemistry, Department of Chemistry, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece; [email protected] 2 International Forensic Research Institute, Department of Chemistry and Biochemistry, Florida International University, 11200 SW 8th St, Miami, FL 33199, USA; akabir@fiu.edu 3 Department of Pharmacy, University “G. d’Annunzio” of Chieti-Pescara, 66100 Chieti, Italy; [email protected] * Correspondence: [email protected]; Tel.: +30-231-099-7698 Received: 30 April 2018; Accepted: 28 May 2018; Published: 4 June 2018 Abstract: Antibiotics are a common practice in veterinary medicine, mainly for therapeutic purposes. Sectors of application include livestock farming, aquacultures, and bee-keeping, where bacterial infections are frequent and can be economically damaging. However, antibiotics are usually administered in sub-therapeutic doses as prophylactic and growth promoting agents. Due to their excessive use, antibiotic residues can be present in foods of animal origin, which include meat, fish, milk, eggs, and honey, posing health risks to consumers. For this reason, authorities have set maximum residue limits (MRLs) of certain antibiotics in food matrices, while analytical methods for their determination have been developed. This work focuses on antibiotic extraction and determination, part of which was presented at the “1st Conference in Chemistry for Graduate, Postgraduate Students and PhD Candidates at the Aristotle University of Thessaloniki”. Taking a step further, this paper is a review of the most recent sample preparation protocols applied for the extraction of sulfonamide antibiotics from food samples and their determination with high-performance liquid chromatography (HPLC), covering a five-year period.
  • Mail Order Maintenance Medication Exclusion List

    Mail Order Maintenance Medication Exclusion List

    Maintenance Medication Exclusion List The following is a list of drugs that are excluded as maintenance medications. Medications which are listed here cannot be filled through the mail order pharmacy for the mail order incentive. This list includes both formulary/preferred and non-formulary/non-preferred medications, and does not provide information regarding the specific coverage, limitations, exclusions or quotas an individual member may have. Some dosage forms and strengths of a particular drug may be considered maintenance medications, whereas others may not. This list is sorted alphabetically by generic drug name. Generic drug names are written in lower case letters. Brand drug names (or some generic drugs with a trade name) are written in CAPITAL letters. Some drugs do not have a brand name available, in such cases the generic name is listed in the “Brand Name” column. This list of drugs should not be used to determine pharmacy benefits, such as prescription copay/coinsurance amounts or formulary status. If you have questions about the formulary status of a medication, or your prescription benefits, please call our Member Services Department at 1-888-681-7878 (toll free). For the hearing or speech impaired: 1-800-521-4874 (toll free TTY). The medications on this list are subject to change at any time. Exclusions: Any formulation that is required to be administered by a skilled medical professional or in a medical office, drugs infused in the home or in an infusion center, drugs that may have other quantity restrictions, any state law that may prohibit the mailing of certain dosage formulation of a drug, drugs that have a high potential for waste and diversion, drugs that require temperature control upon mailing and drugs that require refrigeration.
  • G Protein-Coupled Receptors

    G Protein-Coupled Receptors

    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors Stephen PH Alexander1, Anthony P Davenport2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 3School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.
  • EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use

    EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use

    Ref. Ares(2019)6843167 - 05/11/2019 31 October 2019 EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use Advice on implementing measures under Article 37(4) of Regulation (EU) 2019/6 on veterinary medicinal products – Criteria for the designation of antimicrobials to be reserved for treatment of certain infections in humans Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Introduction On 6 February 2019, the European Commission sent a request to the European Medicines Agency (EMA) for a report on the criteria for the designation of antimicrobials to be reserved for the treatment of certain infections in humans in order to preserve the efficacy of those antimicrobials. The Agency was requested to provide a report by 31 October 2019 containing recommendations to the Commission as to which criteria should be used to determine those antimicrobials to be reserved for treatment of certain infections in humans (this is also referred to as ‘criteria for designating antimicrobials for human use’, ‘restricting antimicrobials to human use’, or ‘reserved for human use only’). The Committee for Medicinal Products for Veterinary Use (CVMP) formed an expert group to prepare the scientific report. The group was composed of seven experts selected from the European network of experts, on the basis of recommendations from the national competent authorities, one expert nominated from European Food Safety Authority (EFSA), one expert nominated by European Centre for Disease Prevention and Control (ECDC), one expert with expertise on human infectious diseases, and two Agency staff members with expertise on development of antimicrobial resistance .